Atlas Trials

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Clinical trial NCT03005782 · COMPLETED

Trial details

NCT number
NCT03005782
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Malignancies
Start date
2016-11-07
Primary completion
2024-04-02
Enrollment
333

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.